Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.54 |
| ▸ | ATIC | P31939 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003575 | 0.91 | PTGDR2 (0.63) | PTGDR2PTGDRATICCCR2 | |
| SCHEMBL2003491 | 0.78 | CHEK1 (0.46) | ALDH1A1LMNA | |
| SCHEMBL2003157 | 0.77 | MAOA (0.44) | ALDH1A1 | |
| SCHEMBL6952238 | 0.72 | PTGDR2 (0.82) | PTGDR2PTGDR | |
| SCHEMBL2006768 | 0.70 | PTGDR (0.53) | PTGDR2PTGDR | |
| SCHEMBL6954682 | 0.69 | PTGDR2 (0.85) | PTGDR2PTGDR | |
| SCHEMBL15965567 | 0.68 | CCR2 (0.55) | PTGDR2PTGDRCCR2 | |
| SCHEMBL28108467 | 0.68 | CHEK1 (0.51) | ALDH1A1 | |
| SCHEMBL12628332 | 0.67 | CHEK1 (0.47) | ALDH1A1 | |
| SCHEMBL13816545 | 0.67 | PTGDR2 (0.64) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | CCL11, LTC4S, TSLP | PTGDR2 253/4885PTGDR 296/4885ATIC 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.